Member Info for 5085

The last roll of the dice will be a savage fund raise 6 - 7p which will but them a year. Fantastic product, let down by various factors, it happens

Dug - holding roadshows throughout the year for BUPA's oncologists

We are at ground level here, remember there are mining companies out there with higher MCaps based on hot air and wishful thinking, we have the tech, rolling all this out won't be easy and so far only talking about 2 markets, invest for the developing story or move on, easy really.

The Pet Cancer Therapeutics Market size is estimated at USD 444.10 million in 2024, and is expected to reach USD 649.82 million by 2029, growing at a CAGR of 7.91% during the forecast period (2024-2029).

The pet cancer therapeutics market was severely affected by the COVID-19 pandemic owing to the cancellations in elective procedures including pet diagnostics and restrictions in veterinary visits. However, the sector has been recovering well since restrictions were lifted. An increase in pet adoption accelerated by the pandemic, increasing research and development activities and product approvals, and increasing pet health awareness have been leading the market recovery over the last two years.

My thoughts are

Selling expensive medical tests, not the same as selling printer ink/winter jackets on Ebay/Amazon.

For many reasons - safety, cost, timeframes, medical and the most important PSE/CiRT are still new, caution needs to be maintained. Otherwise, the burn rate becomes unsustainable and who wants that?

Remember it wasn’t that long ago CiRT tests were being sold by one woman from HR, then someone else joined part time.

The tech, the 2 new products coming to the market soon, the tests sold to date all absolutely brilliant because it will all be ramped up to numbers beyond anyone’s wildest dreams in time, but that comes down the line, but at the same time when we get there the SP will be set accordingly £’s not pence.

So for me, I am delighted with the progress made to date and congratulate the team on their efforts.

Rather than these wild guesses on each and every subject, why not wait until 3 pm :-)

Some amazing stuff

Some good

Some not so good

All normal for a tiny company on their journey to becoming something very much bigger. The gamblers will huff and puff, me well I’m an investor so I will smile and take it all in my stride.

Tricky I don't get those numbers 10% would be $130 in revenue.

According to the last webinar 1% of the PSA market would be equivalent to $25 - $50 million in revenue, meaning 10% would be $250 - $500m

Start at 24m 30s https://www.youtube.com/watch?v=tv1zufLgtQM&t=734s

Https://www.cancersarasota.com/our-physicians/steven-w-mamus-md/

Followed up with this quote

In December 2022, Steven Mamus MD, Medical Director of Oncology/Hematology, Cancer Center of Sarasota (FL, US), an early adopter of the Group's EpiSwitch® CiRT, presented to the Precision Medicine Leaders Summit Liquid Biopsy Virtual Summit on "Navigating the Toughest Challenges of Immunotherapy with the EpiSwitch® CiRT". Giving real-world patient case studies, Dr. Mamus outlined how he is now routinely using EpiSwitch® CiRT in his practice to aid in his decision-making as to optimal treatment courses for his patients.

Those that haven’t read this cover to cover, should https://www.londonstockexchange.com/news-article/OBD/preliminary-results-and-notice-of-agm/15807438

What happened to - the diamonds will cover all debts?

Published yesterday

https://sharelockholmes.substack.com/p/a-small-cap-with-big-potential-oxford

Https://www.youtube.com/watch?v=vMFHvQ73p3g

In time CiRT can save the UK £1bn per year and the US $10bn

The UK’s NHS and private healthcare systems could save significant amounts, estimated to be close to £1bn, by avoiding or reducing the administration rate of ineffective treatments, through straightforward personalised testing. Savings for the US healthcare system could amount to more than $10bn.

I think I will hold for at least 20 years, unless sold

The first-of-its-kind EpiSwitch CiRT blood test predicts the likelihood of a cancer patient’s response to the widely used class of therapeutics – ICIs – including anti-PD-L1 and anti-PD-1 immunotherapies. Using a routine blood test, rather than an invasive biopsy, CiRT provides fast, personalized guidance for a physician on expected efficacy, enabling a more considered decision whether to begin or continue treatment.

The robust EpiSwitch qPCR blood test has demonstrated best-in-class performance, with high sensitivity (93%), specificity (82%), accuracy (85%), and a significant negative predictive value (NPV) of 93% [1], across several ICIs from multiple pharmaceutical companies and more than 15 key oncological indications, including melanoma and lung cancer.

This expansion to the UK follows encouraging early uptake by early adopters of EpiSwitch CiRT in the US where it was first launched in February 2022 as a Laboratory Developed Test (LDT). The CiRT will initially be available as an LDT to private healthcare providers in the UK. It is only available to registered physicians.

An estimated 2.9 million people were living with cancer in the UK in 2020, a prevalence rate expected to rise to 4 million by 2030 (Macmillan Cancer Support). It is estimated that around 350,000 people are diagnosed each year, amounting to over 1,000 new cases per day (Cancer Research UK).

Despite the potential powerful efficacy of ICIs [2], it has been estimated that they are ineffective for up to 70% of patients treated. The situation is exacerbated by ICIs being some of the most highly priced medicines in the world. The bestselling ICI in the UK has a list price of £84,000 per patient course for the drug alone.

The UK’s NHS and private healthcare systems could save significant amounts, estimated to be close to £1bn, by avoiding or reducing the administration rate of ineffective treatments, through straightforward personalised testing. Savings for the US healthcare system could amount to more than $10bn.

https://aithority.com/technology/life-sciences/oxford-biodynamicss-checkpoint-inhibitor-response-test-episwitch-cirt-now-available-in-the-uk/

My basic summary of Episwitch is

There’s an awful lot of information out there in the public domain, a lot of this is undecipherable at our level, but what is undeniable are the facts.

PSE, CiRT, ALS (REFINE – Mitsubishi), Bladder (Javelin 100 – Pizer) and others. Episwitch is a very useful test/tool for the identification and treatment of cancer (FACT). In time I expect there will be 10/20/30 tests available to physicians worldwide, and why not, the beneficiaries are the general public.

This is patent pending document has been translated from Japanese, published 2 weeks ago

https://patents.google.com/patent/JP2023182591A/en?q=(episwitch)&oq=episwitch&sort=new

Massively complicated, this part I found the most interesting

Overview of EpiSwitch™ Technology The EpiSwitch™ platform provides a highly effective means of screening, early detection, companion diagnostics, monitoring and prognostic analysis of major diseases associated with aberrant and responsive gene expression. do. The main advantages of this approach are that it is non-invasive and rapid, due to highly stable DNA-based targets as part of the chromosomal signature rather than unstable protein/RNA molecules.

EpiSwitch™ biomarker signatures exhibit high structural stability, sensitivity, and specificity in stratifying complex disease phenotypes. This technology leverages the latest breakthroughs in epigenetic chemistry, monitoring and evaluation of chromosome conformational signatures as a highly valuable class of epigenetic biomarkers. Current research methodologies deployed in academic settings require 3-7 days of biochemical processing of cellular material to detect CCSs. These procedures limit sensitivity and reproducibility, and further do not have the benefit of targeted insights provided by the EpiSwitch™ analysis package during the design stage.

Page 73

https://issuu.com/thebusinessmag/docs/upload_20231101-155211

Great find Sunshine, thanks

Introduction: Unprecedented advantages in cancer treatments with immune checkpoint

inhibitors (ICI) remain limited to a subset of patients, with high demands for development of

better biomarkers to access likely clinical response in advance of ICI therapeutic

interventions. 3D genomics has emerged as a novel molecular biomarker modality with

strong functional correlation to clinical outcomes. The last few years have seen 3D

genomics applications in patient stratifications, offered solutions in symptomatic and

pre-symptomatic diagnosi and prediction of response to therapeutic interventions.

EpiSwitch® is a 3D genomic platform for the discovery of 3D genomic blood-based

biomarkers in a variety of immune-related and oncological diseases. Objectives: To

develop and validate blood-based predictive 3D genomic biomarkers for response to

PD-(L)-1 checkpoint inhibitors. Methodology: To conduct a genome-wide analyses of the

regulatory 3D genome architecture linked to epigenetics and immunogenetic controls

associated with tumour immune evasion. Several independent cancer patient cohorts

treated with Pembrolizumab, Atezolizumab, Durvalumab, in over 15 diverse oncological

indications were analyzed using EpiSwitch®. Results: A clinical blood assay based on 8

markers - Checkpoint Inhibitor Response Test (CiRT) - has been developed to predict

response to ICI from over 30 million data points. The predictive 8 biomarker set is based on

an observational clinical trial and several retrospective cohorts, representing all together

229 treatments of diverse oncological indications, i.e. melanoma, lung, urethral,

hepatocellular, bladder, prostate, head and neck, colon, breast, bone, brain, lymphoma,

larynx. CiRT has demonstrated high accuracy up to 85%, sensitivity of 93% and specificity

of 82%. Conclusion: This study demonstrates that a 3D genomic approach could be

successfully utilized for development of a non-invasive predictive clinical assay for

response to ICI in cancer patients. CiRT can assist in treatment decisions, help improve

patient selection for optimized treatment, utilize alternative effective treatments, minimize

unnecessary toxicity, and efficiently manage the costs.

Does it really matter what people say, bullish or bearish they are just opinions. These boards are not in place so only those invested can make comment, they are free to use to anyone registering. In the end it is the actions of the company that dictate the share price, not the words of someone.

The new Prostate Screening EpiSwitch or PSE test developed by Oxford Biodynamics is run alongside a standard PSA test to predict the presence or absence of prostate cancer. Oxford Biodynamics’s product has been validated in its Clinical Laboratory Improvement Amendments-certified testing laboratory in Frederick, Maryland. The PSE test is now available for order. Test results take a maximum of five days after a blood sample is received.

Phillip Pierorazio, Section Chief of Urology at Penn Presbyterian Medical Center and Professor of Surgery at the Hospital of the University of Pennsylvania, hopes the PSE test will have an immediate impact.

"Although the traditional PSA has demonstrated clinical utility in prostate cancer screening and monitoring, it also has limitations that are well-described," Pierorzio said in a release. "A more sensitive and specific test would have the potential to increase diagnostic accuracy and address some of the current challenges with prostate cancer screening."

PSE blood test contains 94% predictive accuracy, 97% specificity, and 86% sensitivity to assess the risk of prostate cancer in men. PSA tests possess 55% accuracy, 53% specificity, and 64% sensitivity